|
 |
|
| Home > Pharmaceuticals & Biotechnology |
| |
| |
|
| |
 Pharmaceuticals & Biotechnology Market Research Reports |
The 2011 Coagulation Testing Market: US, Europe, Japan - Emerging Business Opportunities and Market Expansion Strategies for Suppliers
This comprehensive seven-country report is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the coagulation market during the next decade. The report explores business and technological trends in the US, five major European countries (France, Germany, Italy, Spain, UK) and Japan; provides estimates of the test volume, instrument placements and installed base, as well as sales and market shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next ten years....
|
 |
|
$28700.00 |
| |
|
|
|
Transfusion Diagnostic Testing Market: US, Europe, Japan--Emerging Opportunities And Business Expansion Strategies for Suppliers
Rationale During the next ten years, the transfusion diagnostics market will undergo significant transformation, which will result from the convergence of several trends, including more stringent regulations; advances in diagnostic technologies, IT, system engineering and automation; and intensifying competition. Some segments will start resembling commodity markets, where product positioning and differentiation are more critical than underlying technology.
|
|
|
$28600.00 |
| |
|
|
|
The Blood Banking Market: US, Europe, Japan - Emerging Opportunities and Business Development Strategies
During the next ten years, the blood banking market will undergo significant transformation, which will result from the convergence of several trends, including more stringent regulations advances in diagnostic technologies, IT, system engineering and automation and intensifying competition. Some segments will start resembling commodity markets, where product positioning and differentiation is more critical than underlying technology....
|
|
|
$28500.00 |
| |
|
|
|
The 2011 Cancer Diagnostics Market: US, Europe, Japan - Emerging Opportunities and Business Expansion Strategies for Suppliers
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next ten years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field....
|
|
|
$28500.00 |
| |
|
|
|
Global NAT Market
This comprehensive seven-country, 1,050-page report is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the NAT market during this decade.Highlights - Business and technological trends in seven major markets
- Five- and ten-year test volume and sales forecasts
- Market shares of leading competitors
- Feature comparison of major analyzers
- Profiles of market players and start-up firms developing innovative technologies
and products
- Specific product and business opportunities for instrument and consumable suppliers.
|
|
|
$28500.00 |
| |
|
|
|
Hepatitis B Drug Market Forecasts by Country
This model contains ten-year commercial forecasts for hepatitis B drug sales by class, molecule and brand for the US, Japan, France, Germany, Italy, Spain, UK and Turkey. Reasons to Purchase - Understand the changing market dynamics of hepatitis B drugs, and success factors for leading brands....
|
|
|
$15200.00 |
| |
|
|
|
HIV Antiretrovirals Market Forecasts
In 2009, HIV antiretrovirals sales across the seven major markets totalled $11.8 billion, growing at a CAGR of 10....
|
|
|
$15200.00 |
| |
|
|
|
Antihormonal Therapy Market Forecasts
Antihormonal cancer therapies are used predominantly in the treatment of breast and prostate cancers. The high incidence of these tumors translates into a significant commercial potential for drug developers....
|
|
|
$15200.00 |
| |
|
|
|
Cytotoxic Therapies: Drug Launches in Rare Indications to Offset Sales Decline
Growth of cytotoxics will remain static over the forecast period with a CAGR of -0.1%....
|
|
|
$15200.00 |
| |
|
|
|
Antihormonal Cancer Therapies: Leading Brands Strive to Minimize Generic Sales Erosion
Antihormonal cancer therapies are used predominantly in the treatment of breast and prostate cancers. The high incidence of these tumors translates into a significant commercial potential for drug developers....
|
|
|
$15200.00 |
| |
|
|
|
Gastric Cancer
Despite advances in surgery and the use of multimodality therapy, survival outcomes remain poor for gastric cancer patients. There is an urgent need for more effective therapies to improve survival rates in patients presenting with both localized and advanced disease....
|
|
|
$15200.00 |
| |
|
|
|
Spondyloarthropathies: Disease Perception Limits Market
Psoriatic arthritis and ankylosing spondylitis form part of the group of diseases known as the spondyloarthropathies. Psoriatic arthritis is a form of inflammatory arthritis associated with psoriasis, whilst ankylosing spondylitis causes arthritis of the spine and sacroiliac joints....
|
|
|
$15200.00 |
| |
|
|
|
Commercial Insight: Cardiovascular and Metabolic Market Overview
Innovative Development Pipeline Provides Limited Growth
As Primary Care Markets Become Generic
Introduction Datamonitor expects antidiabetic therapies to emerge as the biggest revenue earner in the cardiovascular and metabolic markets by 2018. A large and diverse development pipeline will provide a number of new blockbuster drugs but the heavy genericization of the hypertension and dyslipidemia primary care markets will lead to the overall market only growing by 0....
|
|
|
$15200.00 |
| |
|
|
|
Pharmaceutical Licensing Overview: Risk-Aversion Breeds Creativity as Externalization Intensifies
Big Pharma continues to restructure its internal R&D departments as part of widespread cost-cutting measures to help reduce the impact of the impending 2011 patent cliff. To fill pipeline voids with new products, companies continue to make acquisitions and form partnerships with small pharma, biotech companies and academia, although the relationships between each are becoming increasingly dynamic....
|
|
|
$15200.00 |
| |
|
|
|
The 2011 Top Ten World's Leading Pharmaceutical Companies
A thought-provoking report on performance, capabilities, goals and strategies of the major competitors in the worldwide pharmaceutical market. The report is designed to provide the pharmaceutical industry executives with strategically significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs....
|
|
|
$13200.00 |
| |
|
|
|
The 2011 Top Ten World's Leading Diagnostic Imaging Companies
A unique multi-client study designed to provide diagnostic imaging industry executives with strategically significant competitor information, analysis and insight crucial to the development and implementation of effective business, marketing and R&D programs. The study's major objectives include:- To establish a comprehensive, factual, annually updated and cost-effective information base on performance, capabilities, goals and strategies of the world's leading diagnostic imaging companies....
|
|
|
$12500.00 |
| |
|
|
|
The 2011 Top Ten World's Leading Animal Health Companies
This report provides animal health industry executives with strategically significant competitor information, analysis and insight, critical to the development and implementation of effective marketing and R&D programs.The companies analyzed in the report include: Bayer, Boehringer Ingelhein, Ceva, Elanco, Intervet, Merial, Novartis, Pfizer, Phibro, and Virbac....
|
|
|
$12500.00 |
| |
|
|
|
The 2011 Top Ten World's Leading Life Science Intermediates Companies
A strategic assessment of the competitive environment is widely recognized as one of the highest priority management responsibilities, the task crucial to business survival, growth and profitability. Timely and factual competitive intelligence is vital to the success of all business functions, particularly Planning, Marketing, R&D, and Manufacturing....
|
|
|
$12500.00 |
| |
|
|
|
|